GU Cancers Symposium 2014 Articles

SAN FRANCISCO, CA USA (UroToday.com) - Presented by S. Nilsson,¹ N. Vogelzang,² O. Sartor,³ D. Bottomley,⁴ R. Coleman,⁵ I. Skjorestad,⁶ M. Wahba,⁷ and C. Parker⁸ at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

SAN FRANCISCO, CA USA (UroToday.com) - Presented by Diane Lorraine Borst, Lillian Shahied Arruda, Elizabeth A. MacLean, Yazdi K. Pithavala, James E. Morgado, and Nikhil Sharma at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

SAN FRANCISCO, CA USA (UroToday.com) - Several recently published iterations of the clear cell renal cell carcinoma (ccRCC) genome have demonstrated recurrent mutations in BAP1 and PBRM1. Dr. James Brugarolas presented data regarding the role of these two genes.

SAN FRANCISCO, CA USA (UroToday.com) - Presented by Rana R. McKay, Gustavo Enrique Rodriguez, Xun Lin, Ronit Simantov, and Toni K. Choueiri at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

SAN FRANCISCO, CA USA (UroToday.com) - Presented by Steven E. Finkelstein, Luke T. Nordquist, Shaker R. Dakhil, Nathan B. Green, Elisabeth I. Heath, Ronald Tutrone, Nicholas J. Vogelzang, Andrew J. Armstrong, Matthew R. Cooperberg, Robert Claude Tyler, Robert Brownell Sims, James Boyd Whitmore, and Celestia S. Higano at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

SAN FRANCISCO, CA USA (UroToday.com) - Presented by Reza Mehrazin, Robert G. Uzzo, Alexander Kutikov, Jeffrey J. Tomaszewski, Serge Ginzburg, Karen J. Ruth, Essel Al-Saleem, David Y. T. Chen, Rosalia Viterbo, Richard E. Greenberg, Marc C. Smaldone, and Tahseen I. Al-Saleem at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

SAN FRANCISCO, CA USA (UroToday.com) - Even though observation remains standard of care after partial or radical nephrectomy, those patients who are considered high risk and eligible should be considered for clinical trials for possible neoadjuvant or adjuvant treatments.

SAN FRANCISCO, CA USA (UroToday.com) - Presented by Matthew D. Galsky, MD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

SAN FRANCISCO, CA USA (UroToday.com) - Identification of new therapeutic targets in patients with metastatic bladder cancer is badly needed.